Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728468 · ClinicalTrials.gov registry record · Phase 1
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
A Phase 1 study of Advanced Malignant Solid Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT00728468: Completed Phase 1 study of Advanced Malignant Solid Tumors, sponsored by Pfizer.
NCT00728468 is a Phase 1 study of Advanced Malignant Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00728468, a Phase 1 study of Advanced Malignant Solid Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.
Primary Outcome
Area under the plasma concentration time-curve from time zero (pre-dose) to the last measured concentration (AUClast). Dextrorphan is an active metabolite of dextromethorphan.
Conditions Studied
Interventions
- DRUG PF-00299804
Study Locations (2)
New York
- Roswell Park Cancer Institute - Buffalo
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT00728468 record still lists
NCT00728468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Advanced Malignant Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PF-00299804 is the first listed.
NCT00728468 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00728468 about?
NCT00728468 is a clinical study titled "A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients". Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, an...
What is the current status of trial NCT00728468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-09. Estimated completion is 2014-07.
What conditions does trial NCT00728468 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumors.
What interventions are being tested in trial NCT00728468?
The interventions under investigation include: PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT00728468?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00728468 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00728468's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia